De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalised, according to Dr. Carmen
Continue reading »
Home ยป
Promising clinical trial results of tucatinib with T-DM1 against HER2+ breast cancer
Phase 1b clinical trial results published in JAMA Oncology show promise for the combination of tucatinib (formerly ONT-380) with T-DM1
Continue reading »
Six months of Herceptin could be as effective as 12 months for some women with HER2 positive breast cancer
For women with HER2 positive early-stage breast cancer taking Herceptin for six months could be as effective as 12 months
Continue reading »